TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06940739: A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel

Sponsor: Iovance Biotherapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$8,835,750

Rescue Site Savings

+$5,811,960

Unlock Full NCT06940739 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06940739 Rescue Dossier →